Home » Stocks » PXMD

PaxMedica, Inc. (PXMD)

PaxMedica will go public soon, but the exact IPO date is still unknown.
Stock Price: $5.50 - $6.50
Current IPO price range
Market Cap 59.88M
Revenue (ttm) n/a
Net Income (ttm) -2.15M
Shares Out 9.98M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price $n/a
Previous Close $n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a - n/a
Day's Volume n/a
52-Week Range n/a - n/a

News

There are no news available yet.

About PXMD

PaxMedica is an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). Antipurinergic therapies target the excess production of purines in cells, which can offset homeostasis and result in an overproduction of cellular adenosine triphosphate (or ATP), the main energy molecule in all living cells.

CEO
Howard J. Weisman
Employees
4
Stock Exchange
NASDAQ
Ticker Symbol
PXMD
Full Company Profile